Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. - Wikidata - awgldk - TriplyDB

Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.

Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.

http://www.wikidata.org/entity/Q37402026

about

Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.Anti-myelin oligodendrocyte glycoprotein antibodies: Magnetic resonance imaging findings in a case series and a literature review.Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica.Emerging Role of Immunity in Cerebral Small Vessel Disease.MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder.

P2860

Q33645795-CDCA0C9A-1D0B-491B-B1B9-592173A26240 Q37374434-DFF9F388-1CC0-42BE-8E92-E776804BEAF5 Q38853499-E782B250-E524-4492-8955-6146F1A696F1 Q44875571-451E50DF-435C-492E-90CA-751F33D4883B Q47192132-A9137292-7539-45CA-96A2-03C9EA91EA49 Q49408736-982656D8-E745-4B30-B8D3-950E5E6AE6FC Q55221002-EC87F39B-3D0A-4179-ACB5-83F38FEE2339

P2860

Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.

http://www.wikidata.org/entity/Q37402026

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 February 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.

@en

Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.

@nl

type

label

Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.

@en

Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.

@nl

prefLabel

Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.

@en

Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.

@nl

P1433

Q37402026-2B17E971-0424-4BA5-86CE-013EDEDD8311

P1476

Q37402026-21B1A69E-F2BE-4C65-A7BD-1CCA18CED887

P2093

Q37402026-15D897D7-75F4-4695-8294-8F8CC4D15268

Q37402026-27DE5714-717A-40D1-B482-3EE929E58079

Q37402026-328DE35D-F9A6-4AD0-A5B9-941992FD5860

Q37402026-3A3861E2-B705-463A-B1B3-7B62C246BA95

Q37402026-3C37877B-D665-4801-84DB-7CA510C02CB7

Q37402026-75543CFA-DEA3-449B-BDC8-C774A7758596

Q37402026-81DA3787-AA52-4A97-9AC3-BEBB7236CE0A

Q37402026-8233CDFE-8DC2-48E9-AAFC-88F134DDB1A2

Q37402026-8C61EEBD-F02A-4DE3-8742-23330D644877

Q37402026-B0270937-4658-4BD4-A262-EB34DA280ED3

P2860

Q37402026-0647431D-1276-4DE6-957F-BC8057667CA8

Q37402026-0689651B-9BB1-43B7-A80D-8E679B989B29

Q37402026-191857E3-CFD6-432D-95B9-624F5B5DA7C3

Q37402026-1A843984-78BF-414F-92DC-8C60E4F3625A

Q37402026-376BF18A-4698-408D-9735-74AE5161F3A9

Q37402026-37F812F5-9B93-4F18-9A68-06B7DFBB1169

Q37402026-3CF24C29-93C2-4F05-9FBD-BA2B56C5AF41

Q37402026-44CE494E-B756-4595-B87E-63AFABC43BAB

Q37402026-4A36DF47-A25B-47FF-9C77-EB136F1665D9

Q37402026-540B5427-65CD-41BA-A384-1E83010ABB6D

P2888

Q37402026-7FF7AF27-A42D-4542-8A4D-099D3078AE74

P304

Q37402026-73FBC9FE-0DC7-42B1-8198-2EFDA4967A97

P31

Q37402026-05EC9669-5C3B-4845-A6E8-5BED6F4C0395

P356

Q37402026-5A559E11-8875-4826-AFDF-DADC1C1AA99C

P433

Q37402026-DC482AC3-316A-467F-AE28-FB9078ABF9B8

P478

Q37402026-4383ADEA-04EA-4AFD-9A25-05D53AAE08AA

P577

Q37402026-11C3BBE5-AADF-4129-B594-F9E523E9A379

P698

Q37402026-14A5A7A3-65DB-4158-B4EE-A9CE6E10FEBB

P921

Q37402026-AB69E93C-B2A0-474A-BF62-E8A0A6C1B112

P932

Q37402026-65A1A247-A71A-46EC-BD0F-BFBD608DF5B0

P356

S11427-015-4997-Y

P1433

Science in China. Series C: Life Sciences

P1476

Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.

@en

P2093

Aimee Borazanci

http://www.w3.org/2001/XMLSchema#string

Fu-Dong Shi

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Bennett

http://www.w3.org/2001/XMLSchema#string

Kaibin Shi

http://www.w3.org/2001/XMLSchema#string

Lei Su

http://www.w3.org/2001/XMLSchema#string

Li Yang

http://www.w3.org/2001/XMLSchema#string

Minshu Li

http://www.w3.org/2001/XMLSchema#string

Qiang Liu

http://www.w3.org/2001/XMLSchema#string

Timothy L Vollmer

http://www.w3.org/2001/XMLSchema#string

Yaou Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Aquaporin 4 and neuromyelitis optica

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

Relationship between NMO-antibody and anti-MOG antibody in optic neuritis

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

The spectrum of MOG autoantibody-associated demyelinating diseases

Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology

P2888

s11427-015-4997-y

P304

1270-1281

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11427-015-4997-Y

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26920678

http://www.w3.org/2001/XMLSchema#string

P921

P932

5101174

http://www.w3.org/2001/XMLSchema#string